Diligence memo · auto-generated · as of July 2, 2026
XORTX Therapeutics Inc.
XORTX Therapeutics Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
XORTX Therapeutics Inc. operates in Pharma, based in Calgary.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
XORTX Therapeutics Inc. has raised $2.3M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.8M on 2024-10-18.
Most recent recorded round closed around 2024-10-18.
Valuation (modeled)modeled
Provath models XORTX Therapeutics Inc. at approximately $7.2M (range $1.3M–$18M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.53× the median modeled value of Seed Pharma companies in 2022–2024 (18 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 81 months.
Last raise 20 mo ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
The last round stepped up 3.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 45% of Pharma peers (310 compared).
Modeled value ranks above 30% of those peers.
Closest niche peers: Seal Rock Therapeutics, Inc., Diligent Pharma, Inc., A28 Therapeutics, Inc., Centaurus Therapeutics, Inc., Pathfinder Oncology, Inc..
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.